Recent Quotes (30 days)

You have no recent quotes
chg | %

Sophiris Bio Inc  

(Public, TSE:SHS)   Watch this stock  
Find more results for SHS
- Close
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 4.25 - 18.20
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -4.35
Shares     -
Beta     -
Inst. own     -
Mar 8, 2016
Q4 2015 Sophiris Bio Inc Earnings Release (Estimated) Add to calendar
Jan 29, 2016
Sophiris Bio Inc Review of Topsalysin Clinical Data Conference Call - Webcast
Nov 16, 2015
Q3 2015 Sophiris Bio Inc Earnings Release

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -108.63% -79.27%
Return on average equity -274.64% -111.75%
Employees 9 -
CDP Score - -


1258 Prospect St
LA JOLLA, CA 92037-3609
United States - Map
+1-858-7771760 (Phone)
+1-858-4125693 (Fax)

Website links


Sophiris Bio Inc. is a clinical-stage biopharmaceutical company focused on developing products for the treatment of urological diseases. The Company is developing PRX302 as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia, or BPH, commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer. PRX302, a genetically modified recombinant protein, is delivered via ultrasound-guided injection directly into the prostate. The Company completed placebo-controlled Phase IIb clinical trial of PRX302 for BPH symptoms. The Company is also engaged in the ongoing and planned clinical development in BPH and localized prostate cancer for PLUS-1, a Phase III clinical trial of PRX302 for the treatment of the lower urinary tract symptoms of BPH.

Officers and directors

Lars G. Ekman Chairman of the Board
Age: 65
Randall E. Woods President, Chief Executive Officer, Director
Age: 63
Peter T. Slover CPA Chief Financial Officer
Age: 40
Allison J. Hulme Ph.D. Chief Operating Officer, Head - Research & Development
Age: 52
John Geltosky Ph.D. Independent Director
Age: 69
James L. Heppell Independent Director
Age: 59
Gerald T. Proehl Independent Director
Age: 56
Joseph L. Turner Jr. Independent Director
Age: 63